AMRX - Amneal announces move to Nasdaq
2023-12-15 16:09:17 ET
More on Amneal Pharmaceuticals
- Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
- Amneal Pharma in pact with Strides to launch generic Vascepa
- Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $620M beats by $15.47M
For further details see:
Amneal announces move to Nasdaq